acute lymphoblastic leukemia, asbestos exposure, Breakthrough Therapy designation, cancer, Carl June, CTL019, mesothelioma, Mesothelioma News, myeloma, non-Hodgkin lymphoma, personalized immunotherapy, T-cells, University of Pennsylvania University of Pennsylvania’s Personalized Cellular Therapy Receives FDA’s Breakthrough Therapy Designation By Mesothelioma Cancer Alliance News July 7, 2014 July 7, 2014 Mesothelioma News FDA Designates New Leukemia Treatment as Breakthrough Therapy
